REGENXBIO Quarterly Income Statements Chart
Quarterly
|
Annual
REGENXBIO Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues | ||||||||||||||||||||||||||||||||||||||||
| license and royalty revenue | 18,465,000 | 87,049,000 | 21,214,000 | 24,197,000 | 22,295,000 | 15,622,000 | 22,213,000 | 28,914,000 | 19,977,000 | 19,138,000 | 31,345,000 | 26,512,000 | 32,649,000 | 22,218,000 | 398,655,000 | 30,773,000 | 22,035,000 | 18,884,000 | 21,445,000 | 98,912,000 | 16,566,000 | 17,644,000 | 11,768,000 | 14,700,000 | 7,881,000 | |||||||||||||||
| service revenue | 2,894,000 | 1,963,000 | ||||||||||||||||||||||||||||||||||||||
| total revenues | 21,359,000 | 89,012,000 | 21,214,000 | 24,197,000 | 22,295,000 | 15,622,000 | 22,213,000 | 28,914,000 | 19,977,000 | 19,138,000 | 31,345,000 | 26,512,000 | 32,649,000 | 22,218,000 | 398,655,000 | 30,773,000 | 22,035,000 | 18,884,000 | 21,445,000 | 98,912,000 | 16,566,000 | 17,644,000 | 11,768,000 | 14,700,000 | 7,881,000 | 884,000 | 40,777,000 | 5,306,000 | 40,031,000 | 132,391,000 | 2,040,000 | 1,336,000 | 6,562,000 | 455,000 | 1,696,000 | 125,000 | 2,375,000 | 393,000 | 4,448,000 | 1,140,000 |
| operating expenses | ||||||||||||||||||||||||||||||||||||||||
| cost of license and royalty revenues | 5,209,000 | 3,436,000 | ||||||||||||||||||||||||||||||||||||||
| research and development | 59,500,000 | 53,087,000 | 50,380,000 | 54,429,000 | 48,869,000 | 54,844,000 | 55,681,000 | 58,183,000 | 59,886,000 | 58,516,000 | 62,505,000 | 63,313,000 | 61,008,000 | 55,627,000 | 47,978,000 | 47,855,000 | 45,882,000 | 39,722,000 | 47,180,000 | 43,968,000 | 38,111,000 | 37,035,000 | 33,807,000 | 35,692,000 | 29,483,000 | 25,203,000 | 24,329,000 | 18,508,000 | 21,486,000 | 19,550,000 | 14,170,000 | 12,518,000 | 13,917,000 | 16,619,000 | 16,059,000 | 12,560,000 | 10,680,000 | 6,183,000 | 4,808,000 | 5,664,000 |
| general and administrative | 19,883,000 | 20,347,000 | 20,051,000 | 19,422,000 | 18,855,000 | 18,291,000 | 19,079,000 | 23,083,000 | 23,698,000 | 22,634,000 | 21,210,000 | 20,921,000 | 20,832,000 | 22,318,000 | 22,040,000 | 21,030,000 | 18,425,000 | 17,838,000 | 17,571,000 | 15,859,000 | 15,554,000 | 14,833,000 | 14,450,000 | 12,402,000 | 13,405,000 | 11,558,000 | 11,144,000 | 9,008,000 | 8,318,000 | 8,380,000 | 4,808,000 | 9,444,000 | 6,355,000 | 6,622,000 | 5,742,000 | 6,200,000 | 6,169,000 | 5,479,000 | 4,241,000 | 2,567,000 |
| impairment of long-lived assets | 2,101,000 | |||||||||||||||||||||||||||||||||||||||
| other operating expenses | 45,000 | 15,000 | 833,000 | 37,000 | 29,000 | -34,000 | 118,000 | 220,000 | 26,000 | 33,000 | 50,000 | 67,000 | 44,000 | 8,000 | -62,000 | 11,000 | -2,000 | 5,000 | 28,000 | 42,000 | 29,000 | 45,000 | 34,000 | -2,000 | -20,000 | -114,000 | ||||||||||||||
| total operating expenses | 84,637,000 | 76,885,000 | 72,582,000 | 86,275,000 | 78,332,000 | 79,485,000 | 86,116,000 | 93,874,000 | 93,085,000 | 85,295,000 | 89,116,000 | 97,557,000 | 95,182,000 | 93,745,000 | 85,059,000 | 88,121,000 | 74,261,000 | 62,926,000 | 75,096,000 | 84,961,000 | 58,399,000 | 55,344,000 | 52,092,000 | 50,596,000 | 44,753,000 | 36,790,000 | 38,327,000 | 28,031,000 | 33,681,000 | 30,366,000 | 18,638,000 | 22,645,000 | 21,618,000 | 23,377,000 | 22,165,000 | 18,793,000 | 17,327,000 | 11,644,000 | 9,947,000 | 8,487,000 |
| income from operations | -63,278,000 | 12,127,000 | -51,368,000 | -62,078,000 | -56,037,000 | -63,863,000 | -63,903,000 | -64,960,000 | -73,108,000 | -66,157,000 | -57,771,000 | -71,045,000 | -62,533,000 | -71,527,000 | 313,596,000 | -57,348,000 | -52,226,000 | -44,042,000 | -53,651,000 | 13,951,000 | -41,833,000 | -37,700,000 | -40,324,000 | -35,896,000 | -36,872,000 | -35,906,000 | 2,450,000 | -22,725,000 | 6,350,000 | 102,025,000 | -16,598,000 | -21,309,000 | -15,056,000 | -22,922,000 | -20,469,000 | -18,668,000 | -14,952,000 | -11,251,000 | -5,499,000 | -7,347,000 |
| yoy | 12.92% | -118.99% | -19.62% | -4.44% | -23.35% | -3.47% | 10.61% | -8.56% | 16.91% | -7.51% | -118.42% | 23.88% | 19.74% | 62.41% | -684.51% | -511.07% | 24.84% | 16.82% | 33.05% | -138.87% | 13.45% | 5.00% | -1745.88% | 57.96% | -680.66% | -135.19% | -114.76% | 6.65% | -142.18% | -545.10% | -18.91% | 14.15% | 0.70% | 103.73% | 272.23% | 154.09% | ||||
| qoq | -621.79% | -123.61% | -17.25% | 10.78% | -12.25% | -0.06% | -1.63% | -11.15% | 10.51% | 14.52% | -18.68% | 13.61% | -12.57% | -122.81% | -646.83% | 9.81% | 18.58% | -17.91% | -484.57% | -133.35% | 10.96% | -6.51% | 12.34% | -2.65% | 2.69% | -1565.55% | -110.78% | -457.87% | -93.78% | -714.68% | -22.11% | 41.53% | -34.32% | 11.98% | 9.65% | 24.85% | 32.89% | 104.60% | -25.15% | |
| operating margin % | ||||||||||||||||||||||||||||||||||||||||
| other income | ||||||||||||||||||||||||||||||||||||||||
| interest income from licensing | 21,000 | 25,000 | 83,000 | 25,000 | 29,000 | 37,000 | -141,000 | 56,000 | 40,000 | 70,000 | 77,000 | 18,000 | 153,000 | 94,000 | 19,000 | 117,000 | 554,000 | 29,000 | 130,000 | 1,444,000 | 1,849,000 | 848,000 | 860,000 | 716,000 | 762,000 | 613,000 | 584,000 | 109,000 | 6,898,000 | 1,355,000 | ||||||||||
| investment income | 3,379,000 | 2,501,000 | 9,516,000 | 3,276,000 | 3,468,000 | 2,469,000 | 2,366,000 | 4,660,000 | 2,127,000 | 2,166,000 | 2,026,000 | 1,497,000 | 1,061,000 | 799,000 | 311,000 | 5,535,000 | 399,000 | 580,000 | 13,794,000 | -6,607,000 | 5,722,000 | -3,186,000 | 10,609,000 | 431,000 | 34,524,000 | 2,995,000 | 2,893,000 | 2,122,000 | 1,196,000 | 859,000 | 601,000 | 603,000 | 583,000 | 929,000 | 426,000 | 514,000 | 515,000 | 483,000 | 323,000 | 15,000 |
| interest expense | -10,993,000 | -8,570,000 | -9,417,000 | -820,000 | -449,000 | -1,973,000 | -1,363,000 | -1,624,000 | -1,120,000 | -2,755,000 | -4,310,000 | -5,954,000 | -6,860,000 | -6,130,000 | -6,500,000 | -6,709,000 | -6,366,000 | -6,702,000 | ||||||||||||||||||||||
| total other income | -7,593,000 | -6,044,000 | 182,000 | 2,481,000 | 3,048,000 | 533,000 | 862,000 | 3,092,000 | 1,047,000 | -519,000 | -2,207,000 | -4,439,000 | -5,646,000 | -5,237,000 | -6,170,000 | -1,057,000 | -5,413,000 | -6,093,000 | 13,153,000 | -5,163,000 | 7,571,000 | -2,338,000 | 11,469,000 | 1,147,000 | 35,286,000 | 3,608,000 | 3,477,000 | 2,231,000 | 8,094,000 | 2,214,000 | 601,000 | 603,000 | 583,000 | 929,000 | 426,000 | 514,000 | 515,000 | 483,000 | 323,000 | 15,000 |
| net income | -70,871,000 | 6,083,000 | -51,186,000 | -59,597,000 | -52,989,000 | -63,330,000 | -62,889,000 | -61,868,000 | -72,061,000 | -66,676,000 | -59,935,000 | -75,484,000 | -68,179,000 | -76,723,000 | 294,023,000 | -58,405,000 | -57,639,000 | -50,139,000 | -46,241,000 | 8,791,000 | -33,762,000 | -40,038,000 | -26,464,000 | -34,584,000 | -1,457,000 | -32,228,000 | 4,306,000 | -19,202,000 | 10,594,000 | 104,239,000 | -15,997,000 | -20,706,000 | -14,473,000 | -21,993,000 | -19,608,000 | -18,154,000 | -14,437,000 | -10,768,000 | -5,176,000 | -7,332,000 |
| yoy | 33.75% | -109.61% | -18.61% | -3.67% | -26.47% | -5.02% | 4.93% | -18.04% | 5.69% | -13.10% | -120.38% | 29.24% | 18.29% | 53.02% | -735.85% | -764.37% | 70.72% | 25.23% | 74.73% | -125.42% | 2217.23% | 24.23% | -714.58% | 80.11% | -113.75% | -130.92% | -126.92% | -7.26% | -173.20% | -573.96% | -18.42% | 14.06% | 0.25% | 104.24% | 278.83% | 147.60% | ||||
| qoq | -1265.07% | -111.88% | -14.11% | 12.47% | -16.33% | 0.70% | 1.65% | -14.14% | 8.08% | 11.25% | -20.60% | 10.71% | -11.14% | -126.09% | -603.42% | 1.33% | 14.96% | 8.43% | -626.00% | -126.04% | -15.68% | 51.29% | -23.48% | 2273.64% | -95.48% | -848.44% | -122.42% | -281.25% | -89.84% | -751.62% | -22.74% | 43.07% | -34.19% | 12.16% | 8.01% | 25.75% | 34.07% | 108.04% | -29.41% | |
| net income margin % | ||||||||||||||||||||||||||||||||||||||||
| other comprehensive income | ||||||||||||||||||||||||||||||||||||||||
| unrealized gain on available-for-sale securities | 12,000 | -21,000 | -159,000 | 1,684,000 | 963,000 | 1,200,000 | 2,984,000 | 2,685,000 | 1,524,000 | 3,779,000 | -2,813,000 | -1,284,000 | -30,000 | 113,000 | -623,000 | -487,000 | 1,330,000 | -785,000 | 393,000 | 332,000 | 246,000 | 994,000 | ||||||||||||||||||
| total other comprehensive income | 12,000 | -21,000 | -159,000 | 1,684,000 | 963,000 | 1,200,000 | 2,984,000 | 2,685,000 | 1,524,000 | 3,779,000 | -2,813,000 | -1,284,000 | -30,000 | 113,000 | -623,000 | -487,000 | 1,330,000 | -785,000 | -158,000 | -108,000 | 530,000 | 621,000 | 154,000 | -103,000 | 132,000 | -161,000 | 93,000 | -74,000 | -539,000 | -886,000 | 332,000 | 246,000 | 994,000 | |||||||
| comprehensive loss | -70,859,000 | -51,345,000 | -57,913,000 | -52,026,000 | -62,130,000 | -48,154,250 | -59,183,000 | -70,537,000 | -62,897,000 | -59,018,250 | -78,977,000 | -70,992,000 | -86,104,000 | -57,526,000 | -51,147,000 | -32,432,000 | -40,823,000 | -16,158,000 | -20,613,000 | -14,547,000 | -22,532,000 | -20,494,000 | -17,822,000 | -14,191,000 | -9,774,000 | -5,869,000 | -7,358,000 | |||||||||||||
| net income per share | -1.38 | -1 | -1.17 | -1.05 | -1.38 | -1.15 | -1.41 | -1.66 | -1.53 | -1.278 | -1.75 | -1.58 | -1.79 | -1.36 | -1.2 | |||||||||||||||||||||||||
| weighted-average common shares outstanding, basic and diluted | 51,483 | 49,509 | 50,800 | 50,601 | 45,733 | 43,945 | 43,531 | 43,451 | 43,251 | 43,111 | 42,944 | 42,510 | 41,819 | |||||||||||||||||||||||||||
| comprehensive income | 6,062,000 | 292,739,000 | -58,435,000 | -46,864,000 | 8,304,000 | -26,622,000 | -34,692,000 | -927,000 | -31,607,000 | 4,460,000 | -19,305,000 | 10,726,000 | 104,051,000 | |||||||||||||||||||||||||||
| net income per share | -1.38 | -1 | -1.17 | -1.05 | -1.38 | -1.15 | -1.41 | -1.66 | -1.53 | -1.278 | -1.75 | -1.58 | -1.79 | -1.36 | -1.2 | |||||||||||||||||||||||||
| basic | 0.12 | 6.94 | -1.37 | -1.23 | 0.24 | -0.72 | -0.94 | -0.04 | -0.89 | 0.05 | -0.56 | 0.33 | 3.3 | |||||||||||||||||||||||||||
| diluted | 0.12 | 6.84 | -1.37 | -1.23 | 0.23 | -0.72 | -0.94 | -0.04 | -0.89 | 0.06 | -0.56 | 0.3 | 3.04 | |||||||||||||||||||||||||||
| weighted-average common shares outstanding: | ||||||||||||||||||||||||||||||||||||||||
| basic | 51,362 | 43,734 | 43,152 | 42,438 | 42,629 | 37,281 | 37,342 | 36,690 | 36,813 | 36,669 | 36,366 | 33,427 | 33,988 | 32,082 | 31,632 | |||||||||||||||||||||||||
| diluted | 51,434 | 43,734 | 43,152 | 43,913 | 42,629 | 37,281 | 38,877 | 36,690 | 36,813 | 36,669 | 36,366 | 36,648 | 33,988 | 35,272 | 34,275 | |||||||||||||||||||||||||
| cost of revenues | 6,318,000 | 12,387,000 | 10,579,000 | 4,283,000 | 11,238,000 | 12,388,000 | 9,475,000 | 4,112,000 | 12,783,000 | 13,094,000 | 12,951,000 | 15,717,000 | 23,058,000 | 14,105,000 | 9,819,000 | 4,851,000 | 10,257,000 | 17,364,000 | 4,684,000 | 3,409,000 | 3,791,000 | 2,494,000 | 1,927,000 | |||||||||||||||||
| income before income taxes | -63,041,000 | -61,868,000 | -72,061,000 | -66,676,000 | -59,978,000 | -75,484,000 | -68,179,000 | -76,764,000 | 307,426,000 | -58,405,000 | -57,639,000 | -50,135,000 | -40,498,000 | 8,788,000 | -34,262,000 | -40,038,000 | -28,855,000 | -34,749,000 | -1,586,000 | -32,298,000 | 5,927,000 | -20,494,000 | 14,444,000 | |||||||||||||||||
| income tax benefit | 43,000 | 41,000 | -13,403,000 | -5,743,000 | 3,000 | 500,000 | 2,391,000 | 165,000 | 129,000 | 70,000 | -1,621,000 | 1,292,000 | ||||||||||||||||||||||||||||
| credit losses and other | 175,750 | 229,000 | 391,000 | 83,000 | ||||||||||||||||||||||||||||||||||||
| other comprehensive loss | ||||||||||||||||||||||||||||||||||||||||
| unrealized loss on available-for-sale securities | 2,855,000 | -3,493,000 | -9,381,000 | -1,008,000 | -693,000 | -26,000 | ||||||||||||||||||||||||||||||||||
| total other comprehensive loss | 2,855,000 | -3,493,000 | -9,381,000 | -1,008,000 | -188,000 | -693,000 | -26,000 | |||||||||||||||||||||||||||||||||
| benefit from credit losses and other | 1,445,250 | 5,131,000 | 135,000 | 515,000 | 88,000 | 7,770,000 | ||||||||||||||||||||||||||||||||||
| income tax expense | -4,000 | -3,850,000 | ||||||||||||||||||||||||||||||||||||||
| basic and diluted net income per share | -0.91 | -1.08 | ||||||||||||||||||||||||||||||||||||||
| weighted-average basic and diluted common shares outstanding | 37,257 | 37,104 | ||||||||||||||||||||||||||||||||||||||
| unrealized gain on available-for-sale securities, net of reclassifications and income tax expense | 260,750 | -108,000 | 530,000 | 621,000 | 154,000 | -103,000 | 132,000 | |||||||||||||||||||||||||||||||||
| net income applicable to common stockholders | -26,464,000 | -34,584,000 | -1,457,000 | -32,228,000 | 4,306,000 | -19,202,000 | 10,594,000 | 104,239,000 | -15,997,000 | -20,706,000 | -14,473,000 | -21,993,000 | -19,608,000 | -18,154,000 | -14,437,000 | -10,768,000 | -5,176,000 | -7,332,000 | ||||||||||||||||||||||
| license revenue | 884,000 | 40,777,000 | 5,306,000 | 40,031,000 | 132,391,000 | 2,040,000 | 1,335,000 | 6,555,000 | 455,000 | 1,665,000 | 65,000 | 2,245,000 | 328,000 | 4,390,000 | 65,000 | |||||||||||||||||||||||||
| costs of revenues | ||||||||||||||||||||||||||||||||||||||||
| licensing costs | 29,000 | 2,843,000 | 517,000 | 3,872,000 | 2,408,000 | -382,000 | 683,000 | 1,311,000 | 91,000 | 333,000 | 13,000 | 449,000 | 66,000 | |||||||||||||||||||||||||||
| other revenues | ||||||||||||||||||||||||||||||||||||||||
| expenses | ||||||||||||||||||||||||||||||||||||||||
| other | ||||||||||||||||||||||||||||||||||||||||
| unrealized loss on available-for-sale securities, net of reclassifications and income tax expense | -188,000 | |||||||||||||||||||||||||||||||||||||||
| reagent sales | 47,000 | 107,000 | 59,000 | 57,000 | 61,000 | |||||||||||||||||||||||||||||||||||
| grant revenue | 1,000 | 7,000 | 31,000 | 13,000 | 23,000 | 6,000 | 1,000 | 14,000 | ||||||||||||||||||||||||||||||||
| costs of reagent sales | 6,000 | -3,000 | 22,000 | 49,000 | 30,000 | 4,000 | 44,000 | |||||||||||||||||||||||||||||||||
| unrealized gain on available-for-sale securities, net of reclassifications of 479 and 20 for the nine months ended september 30, 2017 and 2016, respectively | -130,250 | 93,000 | ||||||||||||||||||||||||||||||||||||||
| basic and diluted net income per common share | -510 | -670 | -470 | -820 | -740 | -690 | -550 | -410 | 2,890 | -1,520 | ||||||||||||||||||||||||||||||
| weighted-average basic and diluted common shares | 29,878,000 | 30,940,000 | 30,662,000 | 26,673,000 | 26,409,000 | 26,469,000 | 26,362,000 | 26,327,000 | 9,173,000 | 4,809,000 | ||||||||||||||||||||||||||||||
| unrealized gain on available-for-sale securities, net of reclassifications of 480 for the six months ended june 30, 2017 | -74,000 | |||||||||||||||||||||||||||||||||||||||
| unrealized gain on available-for-sale securities, net of reclassifications of 480 for the three months ended march 31, 2017 | -539,000 | |||||||||||||||||||||||||||||||||||||||
| license revenue from related party | 1,000,000 | |||||||||||||||||||||||||||||||||||||||
| reconciliation of net income to net income applicable to common stockholders | ||||||||||||||||||||||||||||||||||||||||
| net accretion and dividends on convertible preferred stock | ||||||||||||||||||||||||||||||||||||||||
| net gain on extinguishment of convertible preferred stock | ||||||||||||||||||||||||||||||||||||||||
| net decretion and dividends on convertible preferred stock | ||||||||||||||||||||||||||||||||||||||||
| licensing costs to related parties | 131,750 | 213,000 | ||||||||||||||||||||||||||||||||||||||
| foreign currency transaction losses | 16,000 | 4,000 | ||||||||||||||||||||||||||||||||||||||
| other operating income | -5,000 | |||||||||||||||||||||||||||||||||||||||
| accretion and dividends on convertible preferred stock |
We provide you with 20 years income statements for REGENXBIO stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of REGENXBIO stock. Explore the full financial landscape of REGENXBIO stock with our expertly curated income statements.
The information provided in this report about REGENXBIO stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.